Atea Pharmaceuticals, Inc.
About Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2021
- $351.4M
- Net income
- -$158.3M
- Total assets
- $315.2M
- Market cap
- $340.1M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $180.9M
- Operating income
- -$180.9M
- Income tax
- -$6.2M
- Net income
- -$158.3M
- EPS (basic)
- $-1.94
- EPS (diluted)
- $-1.94
Balance sheet
- Total assets
- $315.2M
- Current assets
- $311.0M
- Total liabilities
- $39.8M
- Current liabilities
- $39.8M
- Shareholders’ equity
- $275.4M
Cash flow
- Operating cash flow
- -$132.0M
- Investing cash flow
- $188.8M
- Financing cash flow
- -$25.7M
- Net cash flow
- $31.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $340.1M
- EPS (diluted)
- $-1.94
- Shares outstanding
- 78.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 30, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $158.3M in FY2021.
- Trading 30% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Atea Pharmaceuticals, Inc..
Write a review
News about Atea Pharmaceuticals, Inc.
News & sentiment via Polygon.io
